Literature DB >> 23753624

Contribution of interleukin-12 p35 (IL-12p35) and IL-12p40 to protective immunity and pathology in mice infected with Chlamydia muridarum.

Lili Chen1, Lei Lei, Zhou Zhou, Jie He, Sha Xu, Chunxue Lu, Jianlin Chen, Zhangsheng Yang, Gangqiu Wu, I-Tien Yeh, Guangming Zhong, Yimou Wu.   

Abstract

The p35 molecule is unique to interleukin-12 (IL-12), while p40 is shared by both IL-12 and IL-23. IL-12 promotes Th1 T cell responses, while IL-23 promotes Th17 T cell responses. The roles of IL-12p35- and IL-12p40-mediated responses in chlamydial infection were compared in mice following an intravaginal infection with Chlamydia muridarum. Mice deficient in either IL-12p35 or p40 both developed similar but prolonged infection time courses, confirming the roles of IL-12-mediated immune responses in clearing primary infection. However, all mice, regardless of genotype, cleared reinfection within 2 weeks, suggesting that an IL-12- or IL-23-independent adaptive immunity is protective against chlamydial infection. All infected mice developed severe oviduct hydrosalpinx despite the increased Th2 responses in IL-12p35- or IL-12p40-deficient mice, suggesting that Th2-dominant responses can contribute to Chlamydia-induced inflammatory pathology. Compared to IL-12p35 knockout mice, the IL-12p40-deficient mice exhibited more extensive spreading of chlamydial organisms into kidney tissues, leading to significantly increased incidence of pyelonephritis, which both confirms the role of IL-12 or IL-23-independent host responses in Chlamydia-induced pathologies and suggests that in the absence of IL-12/IFN-γ-mediated Th1 immunity, an IL-23-mediated response may play an important role in restricting chlamydial organisms from spreading into distal organs. These observations together provide important information for both understanding chlamydial pathogenesis and developing anti-Chlamydia vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23753624      PMCID: PMC3719579          DOI: 10.1128/IAI.00161-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  PCR studies on the presence of Chlamydia trachomatis in the upper urinary tract of patients with obstructive pyelonephritis.

Authors:  J Dimitrakov; V Ganev; T Zlatanov; I Detchev; A Horvat; S Kirov; I Vatchkova; D Dimitrakov
Journal:  Folia Med (Plovdiv)       Date:  1998

3.  Immunoaccessible peptide sequences of the major outer membrane protein from Chlamydia trachomatis serovar C.

Authors:  G M Zhong; R C Brunham
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Sexually transmitted diseases and tubal pregnancy.

Authors:  K J Sherman; J R Daling; A Stergachis; N S Weiss; H M Foy; S P Wang; J T Grayston
Journal:  Sex Transm Dis       Date:  1990 Jul-Sep       Impact factor: 2.830

5.  Dendritic cells pulsed with a recombinant chlamydial major outer membrane protein antigen elicit a CD4(+) type 2 rather than type 1 immune response that is not protective.

Authors:  Jennifer Shaw; Vernon Grund; Luke Durling; Debbie Crane; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis.

Authors:  G Zhong; I Toth; R Reid; R C Brunham
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

7.  Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria.

Authors:  Rajatava Basu; Darrell B O'Quinn; Daniel J Silberger; Trenton R Schoeb; Lynette Fouser; Wenjun Ouyang; Robin D Hatton; Casey T Weaver
Journal:  Immunity       Date:  2012-11-29       Impact factor: 31.745

8.  IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12.

Authors:  Linda A Lieberman; Fabiola Cardillo; Alexander M Owyang; Donna M Rennick; Daniel J Cua; Robert A Kastelein; Christopher A Hunter
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

Review 9.  The biology of IL-12: coordinating innate and adaptive immune responses.

Authors:  Wendy T Watford; Masato Moriguchi; Akio Morinobu; John J O'Shea
Journal:  Cytokine Growth Factor Rev       Date:  2003-10       Impact factor: 7.638

10.  Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors.

Authors:  G Zhong; P Fan; H Ji; F Dong; Y Huang
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  13 in total

1.  Antigen-Specific CD4+ T Cell-Derived Gamma Interferon Is Both Necessary and Sufficient for Clearing Chlamydia from the Small Intestine but Not the Large Intestine.

Authors:  Hui Lin; Conghui He; John J Koprivsek; Jianlin Chen; Zhiguang Zhou; Bernard Arulanandam; Zhenming Xu; Lingli Tang; Guangming Zhong
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  Nonpathogenic Colonization with Chlamydia in the Gastrointestinal Tract as Oral Vaccination for Inducing Transmucosal Protection.

Authors:  Luying Wang; Cuiming Zhu; Tianyuan Zhang; Qi Tian; Nu Zhang; Sandra Morrison; Richard Morrison; Min Xue; Guangming Zhong
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

Review 3.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

4.  Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells.

Authors:  Saurabh Dixit; Rajnish Sahu; Richa Verma; Skyla Duncan; Guillermo H Giambartolomei; Shree R Singh; Vida A Dennis
Journal:  Biomaterials       Date:  2017-12-26       Impact factor: 12.479

5.  Lack of long-lasting hydrosalpinx in A/J mice correlates with rapid but transient chlamydial ascension and neutrophil recruitment in the oviduct following intravaginal inoculation with Chlamydia muridarum.

Authors:  Hongbo Zhang; Zhou Zhou; Jianlin Chen; Ganqiu Wu; Zhangsheng Yang; Zhiguang Zhou; Joel Baseman; Jin Zhang; Robert Lee Reddick; Guangming Zhong
Journal:  Infect Immun       Date:  2014-04-07       Impact factor: 3.441

6.  Murine MicroRNA-214 regulates intracellular adhesion molecule (ICAM1) gene expression in genital Chlamydia muridarum infection.

Authors:  Tanvi Arkatkar; Rishein Gupta; Weidang Li; Jieh-Juen Yu; Shradha Wali; M Neal Guentzel; James P Chambers; Lane K Christenson; Bernard P Arulanandam
Journal:  Immunology       Date:  2015-06-29       Impact factor: 7.397

7.  In Vivo and Ex Vivo Imaging Reveals a Long-Lasting Chlamydial Infection in the Mouse Gastrointestinal Tract following Genital Tract Inoculation.

Authors:  Qi Zhang; Yumeng Huang; Siqi Gong; Zhangsheng Yang; Xin Sun; Robert Schenken; Guangming Zhong
Journal:  Infect Immun       Date:  2015-06-22       Impact factor: 3.441

8.  Signaling via tumor necrosis factor receptor 1 but not Toll-like receptor 2 contributes significantly to hydrosalpinx development following Chlamydia muridarum infection.

Authors:  Xiaohua Dong; Yuanjun Liu; Xiaotong Chang; Lei Lei; Guangming Zhong
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

9.  Induction of protective immunity against Chlamydia muridarum intracervical infection in DBA/1j mice.

Authors:  Lingli Tang; Zhangsheng Yang; Hongbo Zhang; Zhiguang Zhou; Bernard Arulanandam; Joel Baseman; Guangming Zhong
Journal:  Vaccine       Date:  2013-11-01       Impact factor: 3.641

Review 10.  Immunopathogenesis of genital Chlamydia infection: insights from mouse models.

Authors:  Jacob Dockterman; Jörn Coers
Journal:  Pathog Dis       Date:  2021-03-31       Impact factor: 3.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.